OrgaranOrgaran (Danaparoid Sodium). This site is for UK health care professionals only.

Safety of Orgaran



Help safeguard public health and support medicines yellow card reporting. www.yellowcard.gov.uk Alternatively adverse events can be reported to Organon Laboratories by calling 01223 432740.

See SmPC for full details

Contraindications

  • Hypersensitivity to danaparoid sodium or any ingredients of Orgaran.


  • In patients receiving Orgaran for treatment rather than for prophylaxis, locoregional anaesthesia in elective surgical procedures is contra-indicated. Severe haemorrhagic diathesis, unless the patient also has HIT. Haemorrhagic stroke in the acute phase.


  • Uncontrollable active bleeding state. Severe renal and/or hepatic insufficiency, unless the patient also has HIT. Severe hypertension.


  • Acute bacterial endocarditis.


  • A positive in vitro aggregation test for the heparin-induced antibody in the presence of Orgaran in patients with a history of thrombocytopenia induced by heparin or heparin-like anticoagulants.


  • Precautions and warnings:

  • Use with caution in patients with moderately impaired renal, and/or liver function with impaired haemostasis, ulcerative lesions of the gastro-intestinal tract or other diseases which may lead to an increased danger of haemorrhage into a vital organ or site.


  • Contains sodium sulphite, asthma patients hypersensitive to sulphite may be at risk of bronchospasm and/or anaphylactic shock.


  • Check the number of platelets regularly.


  • If antibody-induced thrombocytopenia occurs, stop the use of Orgaran.


  • Orgaran should not be given by the intramuscular route.


  • Safety and efficacy in patients with non-haemorrhagic stroke not confirmed.


  • Interactions:

  • No clinically significant interactions with other medications have been found.


  • Pregnancy & Lactation:

  • Not recommended during pregnancy and lactation.


  • Adverse reactions:

  • Enhanced bleeding or haematoma at the operation site.


  • Bruising and/or pain at injection sites.


  • Skin rashes.


  • Other local or generalised hypersensitivity reactions.


  • Antibody induced thrombocytopenia.


  • Liver abnormalities without clinical significance.


  • Very rarely, cases of epidural and spinal haematomas.


  • Overdosage:

  • In the event of serious bleeding other than caused by a surgical error, Orgaran should be stopped and a blood transfusion should be considered.

Contact information

Organon Laboratories Ltd
Cambridge Science Park
Milton Road
Cambridge
CB4 0FL
Telephone 01223 432700
Fax 01223 424368
(www.organon.co.uk)


© 2008 Organon Laboratories. All rights reserved. Date of prep. November 2008. Item code: 09847G